Home › Companies › DENALI THERAPEUTICS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and DENALI THERAPEUTICS INC.’s Form 8-K, filed June 3, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 3, 2025: 5 items on DENALI THERAPEUTICS INC.’s Form 8-K, filed June 3, 2025: 3 elected · 2 approved.
Significant dissent: 1 director (46.4% against).
Notable dissent: 2 directors (18.9%, 12.1% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore DENALI THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are DENALI THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 3, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Julian Baker | 98,032,346 | -- | -- | 22,859,131 | 10,176,385 | 81% | Elected | — |
| Elect Director: Peter Klein | 106,248,604 | -- | -- | 14,642,873 | 10,176,385 | 88% | Elected | — |
| Elect Director: Steve Krognes | 64,815,389 | -- | -- | 56,076,088 | 10,176,385 | 53.6% | Elected | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 | 130,831,208 | 194,182 | 42,472 | -- | -- | 99.9% | Approved | — |
| 3. Advisory Vote to Approve Executive Compensation | 109,412,774 | 10,796,945 | 681,758 | -- | 10,176,385 | 91% | Approved | — |
Source: DENALI THERAPEUTICS INC., Form 8-K, filed with the SEC on June 3, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
251 asset managers disclosed a vote on at least one DENALI THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Julian Baker
DENALI THERAPEUTICS INC.’s own tally for this item (“Elect Director: Julian Baker”): 98,032,346 for, 22,859,131 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class II director, to hold office until the Company's 2028 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 44,219,761 for, 13,201,551 withheld, 96,204 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,510,350 | 0 | 0 | 10,728,901 | Mixed |
| Fidelity | 8,000,813 | 0 | 0 | 0 | For |
| BlackRock | 4,793,387 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,069,138 | 0 | 0 | 0 | For |
| Capital Group | 3,462,006 | 0 | 0 | 0 | For |
| State Street | 1,502,864 | 0 | 0 | 58 | For |
| AllianceBernstein | 0 | 0 | 0 | 1,057,610 | Withhold |
| NEW ECONOMY FUND | 1,024,429 | 0 | 0 | 0 | For |
| Charles Schwab | 1,015,514 | 0 | 0 | 0 | For |
| Dimensional | 779,940 | 0 | 0 | 0 | For |
| Aberdeen | 759,815 | 0 | 0 | 0 | For |
| Principal | 506,100 | 0 | 0 | 209,758 | Mixed |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 614,855 | Withhold |
| Equitable | 231,406 | 0 | 0 | 370,890 | Mixed |
| BNY Mellon | 446,002 | 0 | 0 | 0 | For |
| Artisan | 423,041 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 318,239 | 0 | 0 | 0 | For |
| TIAA | 316,575 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 211,929 | 0 | 0 | 0 | For |
| Brighthouse | 170,393 | 0 | 0 | 10,141 | Mixed |
| Lincoln Financial | 155,863 | 0 | 0 | 0 | For |
| American Century | 136,150 | 0 | 0 | 0 | For |
| New York Life | 91,344 | 0 | 0 | 26,144 | Mixed |
| Jackson National | 111,797 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 111,375 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Peter Klein
DENALI THERAPEUTICS INC.’s own tally for this item (“Elect Director: Peter Klein”): 106,248,604 for, 14,642,873 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class II director, to hold office until the Company's 2028 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 52,697,344 for, 4,788,854 withheld, 31,319 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 25,239,251 | 0 | 0 | 0 | For |
| Fidelity | 8,000,813 | 0 | 0 | 0 | For |
| BlackRock | 4,793,387 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,069,138 | 0 | 0 | 0 | For |
| Capital Group | 3,462,006 | 0 | 0 | 0 | For |
| State Street | 5,135 | 0 | 0 | 1,497,787 | Withhold |
| AllianceBernstein | 0 | 0 | 0 | 1,057,610 | Withhold |
| NEW ECONOMY FUND | 1,024,429 | 0 | 0 | 0 | For |
| Charles Schwab | 1,015,514 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 779,940 | Withhold |
| Aberdeen | 759,815 | 0 | 0 | 0 | For |
| Principal | 506,374 | 0 | 0 | 209,484 | Mixed |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 614,855 | Withhold |
| Equitable | 231,406 | 0 | 0 | 370,890 | Mixed |
| BNY Mellon | 446,002 | 0 | 0 | 0 | For |
| Artisan | 423,041 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 318,239 | 0 | 0 | 0 | For |
| TIAA | 316,575 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 211,929 | 0 | 0 | 0 | For |
| Brighthouse | 180,534 | 0 | 0 | 0 | For |
| Lincoln Financial | 55,931 | 0 | 0 | 99,932 | Mixed |
| American Century | 136,150 | 0 | 0 | 0 | For |
| New York Life | 117,488 | 0 | 0 | 0 | For |
| Jackson National | 86,251 | 0 | 25,546 | 0 | Mixed |
| ALPS ETF Trust | 111,375 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
53.6% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Steve Krognes
DENALI THERAPEUTICS INC.’s own tally for this item (“Elect Director: Steve Krognes”): 64,815,389 for, 56,076,088 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class II director, to hold office until the Company's 2028 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 53.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 21,924,797 for, 30,243,117 withheld, 5,349,603 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 13,755,701 | 0 | 0 | 11,483,549 | Mixed |
| Fidelity | 0 | 0 | 0 | 8,000,813 | Withhold |
| BlackRock | 0 | 0 | 4,793,387 | 0 | Abstain |
| T. Rowe Price | 0 | 0 | 0 | 4,069,138 | Withhold |
| Capital Group | 3,462,006 | 0 | 0 | 0 | For |
| State Street | 3,472 | 0 | 0 | 1,499,450 | Withhold |
| AllianceBernstein | 1,057,610 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 1,024,429 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 1,015,514 | Withhold |
| Dimensional | 0 | 0 | 0 | 779,940 | Withhold |
| Aberdeen | 0 | 0 | 0 | 759,815 | Withhold |
| Principal | 209,758 | 0 | 0 | 506,100 | Mixed |
| AB DISCOVERY GROWTH FUND, INC. | 614,855 | 0 | 0 | 0 | For |
| Equitable | 370,890 | 0 | 0 | 231,406 | Mixed |
| BNY Mellon | 446,002 | 0 | 0 | 0 | For |
| Artisan | 423,041 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 318,239 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 316,575 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 211,929 | 0 | Abstain |
| Brighthouse | 0 | 0 | 0 | 180,534 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 155,863 | Withhold |
| American Century | 0 | 0 | 0 | 136,150 | Withhold |
| New York Life | 26,144 | 0 | 0 | 91,344 | Mixed |
| Jackson National | 2,107 | 0 | 109,690 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 0 | 111,375 | Withhold |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
91% Approved · of votes cast
Prior year: 92.2% for (May 31, 2024 meeting) ▼ 1.2 pts
Description as filed by funds: Advisory Vote to Ratify Named Executive Officers' Compensation
DENALI THERAPEUTICS INC.’s own tally for this item (“3. Advisory Vote to Approve Executive Compensation”): 109,412,774 for, 10,796,945 against — passed, per its Form 8-K filed June 3, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Advisory Vote to Approve Executive Compensation The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 25,239,251 | 0 | 0 | 0 | For |
| Fidelity | 8,000,813 | 0 | 0 | 0 | For |
| BlackRock | 4,793,387 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,069,138 | 0 | 0 | 0 | For |
| Capital Group | 0 | 3,462,006 | 0 | 0 | Against |
| State Street | 1,502,922 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,057,610 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 0 | 1,024,429 | 0 | 0 | Against |
| Charles Schwab | 1,015,514 | 0 | 0 | 0 | For |
| Dimensional | 779,940 | 0 | 0 | 0 | For |
| Aberdeen | 759,815 | 0 | 0 | 0 | For |
| Principal | 715,858 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 614,855 | 0 | 0 | 0 | For |
| Equitable | 602,296 | 0 | 0 | 0 | For |
| BNY Mellon | 446,002 | 0 | 0 | 0 | For |
| Artisan | 423,041 | 0 | 0 | 0 | For |
| TIAA | 316,575 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 211,929 | 0 | 0 | 0 | For |
| Brighthouse | 180,534 | 0 | 0 | 0 | For |
| Lincoln Financial | 155,863 | 0 | 0 | 0 | For |
| American Century | 136,150 | 0 | 0 | 0 | For |
| New York Life | 117,488 | 0 | 0 | 0 | For |
| Jackson National | 111,797 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 111,375 | 0 | 0 | 0 | For |
| Segall Bryant & Hamill Trust | 93,536 | 0 | 0 | 0 | For |
Fund voting reports, all 70 managers: 52,637,371 for, 4,523,612 against, 38,295 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Wellington | 12,223,224 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD & CO LTD | 8,466,903 | 0 | 0 | 0 | For |
| Fidelity | 7,479,161 | 0 | 0 | 0 | For |
| Temasek Holdings (Private) Ltd | 5,355,832 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,306,779 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 0 | 4,542,711 | 0 | 0 | Against |
| State Street | 3,941,976 | 0 | 0 | 0 | For |
| BlackRock | 3,861,412 | 0 | 0 | 0 | For |
| UBS | 0 | 3,798,232 | 0 | 0 | Against |
| BAKER BROS. ADVISORS LP | 3,731,695 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD OVERSEAS LTD | 3,047,937 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,988,636 | 0 | 0 | 0 | For |
| AllianceBernstein | 2,899,336 | 0 | 0 | 0 | For |
| Camber Capital Management LP | 1,250,000 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 1,114,693 | 0 | 0 | 0 | For |
| Charles Schwab | 1,033,670 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 992,536 | 0 | 0 | 0 | For |
| Casdin Capital, LLC | 890,000 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 858,162 | 0 | 0 | Against |
| Aberdeen | 759,815 | 0 | 0 | 0 | For |
| Northern Trust | 753,168 | 0 | 0 | 0 | For |
| Citadel | 730,597 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 728,999 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 721,304 | 0 | 0 | 0 | For |
| Cercano Management LLC | 625,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 203 managers: 76,415,858 for, 10,025,008 against, 1,347 abstained, 4,363 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 99.8% for (May 31, 2024 meeting) ▲ 0.1 pts
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2025
DENALI THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, ”): 130,831,208 for, 194,182 against — passed, per its Form 8-K filed June 3, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified based on the following results of voting:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 57,441,987 for, 37,235 against, 38,295 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 25,239,251 | 0 | 0 | 0 | For |
| Fidelity | 8,000,813 | 0 | 0 | 0 | For |
| BlackRock | 4,793,387 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,069,138 | 0 | 0 | 0 | For |
| Capital Group | 3,462,006 | 0 | 0 | 0 | For |
| State Street | 1,502,864 | 58 | 0 | 0 | For |
| AllianceBernstein | 1,057,610 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 1,024,429 | 0 | 0 | 0 | For |
| Charles Schwab | 1,015,514 | 0 | 0 | 0 | For |
| Dimensional | 779,940 | 0 | 0 | 0 | For |
| Aberdeen | 759,815 | 0 | 0 | 0 | For |
| Principal | 715,858 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 614,855 | 0 | 0 | 0 | For |
| Equitable | 602,296 | 0 | 0 | 0 | For |
| BNY Mellon | 446,002 | 0 | 0 | 0 | For |
| Artisan | 423,041 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 318,239 | 0 | 0 | 0 | For |
| TIAA | 316,575 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 211,929 | 0 | 0 | 0 | For |
| Brighthouse | 180,534 | 0 | 0 | 0 | For |
| Lincoln Financial | 155,863 | 0 | 0 | 0 | For |
| American Century | 136,150 | 0 | 0 | 0 | For |
| New York Life | 117,488 | 0 | 0 | 0 | For |
| Jackson National | 111,797 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 111,375 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 145,251,258 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 17.38% |
| 2 | Fidelity | 5.51% |
| 3 | BlackRock | 3.30% |
| 4 | T. Rowe Price | 2.80% |
| 5 | Capital Group | 2.38% |
| 6 | State Street | 1.03% |
| 7 | AllianceBernstein | 0.73% |
| 8 | NEW ECONOMY FUND | 0.71% |
| 9 | Charles Schwab | 0.70% |
| 10 | Dimensional | 0.54% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Wellington | 8.42% |
| 2 | BAILLIE GIFFORD & CO LTD | 5.83% |
| 3 | Fidelity | 5.15% |
| 4 | Temasek Holdings (Private) Ltd | 3.69% |
| 5 | T. Rowe Price | 3.65% |
| 6 | Capital Research Global Investors | 3.13% |
| 7 | State Street | 2.71% |
| 8 | BlackRock | 2.66% |
| 9 | UBS | 2.61% |
| 10 | BAKER BROS. ADVISORS LP | 2.57% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 13,834,956 | 9.52% | Form 13F, quarter ended March 31, 2025 |
| BAILLIE GIFFORD & CO | 12,313,931 | 8.48% | Schedule 13G, filed February 12, 2025 |
| Vanguard Group | 11,799,757 | 8.12% | Form 13F, quarter ended March 31, 2025 |
| Wellington Management | 11,409,598 | 7.86% | Form 13F, quarter ended March 31, 2025 |
| Wellington | 10,727,450 | 7.39% | Proxy statement (DEF 14A), proxy filed April 17, 2025 |
| FMR LLC | 10,141,901 | 6.98% | Proxy statement (DEF 14A), proxy filed April 17, 2025 |
| Julian C. Baker | 7,431,485 | 5.12% | Proxy statement (DEF 14A), proxy filed April 17, 2025 |
| FMR (Fidelity) | 7,413,354 | 5.10% | Form 13F, quarter ended March 31, 2025 |
| Ryan J. Watts, Ph.D. | 4,545,835 | 3.13% | Proxy statement (DEF 14A), proxy filed April 17, 2025 |
| State Street | 4,460,757 | 3.07% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 145,251,258 shares outstanding, as reported by DENALI THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At DENALI THERAPEUTICS INC.'s shareholder meeting held June 3, 2025, in the 2024-2025 proxy season, 251 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,630 separate fund positions. On the most widely held item on that ballot — Advisory Vote to Ratify Named Executive Officers' Compensation — DENALI THERAPEUTICS INC.'s filing reports the proposal as approved, with 91% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: DENALI THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 3, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from DENALI THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
DENALI THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “DENALI THERAPEUTICS (DNLI) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/denali-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.